NovAb, Inc. long term focus is to develop a cellular immunotherapy platform technology for treating a broad spectrum of cancer types. NovAb's scientific founders discovered a novel adaptive immune system in jawless vertebrates, lamprey and hagfish, that uses Variable Lymphocyte Receptors (VLRs) composed of leucine-rich repeats for antigen recognition instead of immunoglobulin (Ig) antibodies found in all jawed vertebrates.
